Covid-19 vaccine: A race against time

ET Bureau|
Repurposing existing drugs
1/6

Repurposing existing drugs

With vaccines being the need of the hour to combat the Covid-19 virus, a number of companies have come forward to develop potential candidates. Faced with surging infections every day around the globe, some companies are repurposing existing drugs to fast-track a cure. Divya Rajagopal brings you an update on corporates, governments and drug companies which are currently in a race against time to develop a vaccine.

Getty Images
US
2/6

US

Hydroxychloroquine has been a contested drug used by patients of lupus and rheumatoid arthritis. The drug received emergency approval from USFDA despite opposition from a few experts who say there is too little evidence to prove the efficacy of the drug.

Getty Images
J&J & BARDA
3/6

J&J & BARDA

Jansen, the research arm of drugmaker J&J, and USA’s Biomedical Advanced Research and Development Authority (BARDA) are investing $1 billion in vaccine development. The experimental work on the candidate will begin from September this year and it will work on the same platform technology which was used for developing the vaccine for Ebola.

Shutterstock.com
Laurus Labs
4/6

Laurus Labs

Rising Pharma, the US partner of Hyderabad-based Laurus Labs, announced on Tuesday its collaborative agreement with the Division of Infectious Disease and International Medicine at the University of Minnesota on a clinical trial exploring hydroxychloroquine as a preventive treatment.

Getty Images
ICMR-CSIR Consortium
5/6

ICMR-CSIR Consortium

The department of biotechnology, Council of Scientific and Industrial Research and ICMR are working on developing a vaccine for Covid-19. The consortium will support the development of medical equipment, diagnostics, therapeutics, drugs and vaccines to meet the healthcare challenges of Covid-19. It also said the vaccine development is being supported by three Indian industries. Research on therapeutic and drug development has started.

Shutterstock.com
Intas Pharma
6/6

Intas Pharma

The Ahmedabad-based Intas Pharma has said that it is collaborating with a WHO-endorsed study in the prevention of Covid-19 using hydroxychloroquine. The global COPCOV (chloroquine / hydroxychloroquine prevention of COVID-19 in the healthcare setting) study involves 40,000 frontline healthcare workers who are caring for Covid-19 patients and is due to start shortly. COPCOV will be led by scientists from the University of Oxford and funded by the Wellcome Trust

Getty Images

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service

X
User